Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INR102 in PSMA-Positive mCRPC
NCT06970119Phase 2Recruiting
- Sponsor
- Yunhe Pharmaceutical
- Start
- May 2025
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of INR102 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Yunhe Pharmaceutical. Started May 2025; status: recruiting.
02
Drugs
INR102
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06970119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06970119.